VBI Vaccines updates on glioblastoma vax progress; Scripps team nets $1.6M for heroin addiction vaccine;

> Cambridge, MA-based VBI Vaccines ($VBIV) said data confirm the "desired integrity and quality" of its candidate glioblastoma vaccine; it has a pre-IND meeting with the FDA in the first half of 2016. Release

> A team at The Scripps Research Institute received $1.6 million through the Translational Avant-Garde Award program to work on a vaccine to combat heroin addiction. Report

> The Sabin Vaccine Institute, through its Product Development Partnership, teamed up with King Saud University to grow vaccine research capabilities in the Middle East. Report

> Baltimore, MD-based Vaccinogen signed on with Dublin City University to get its hands on the biotechnology analysis platform DiCast. Report

> Memphis, TN-based Hapten Sciences announced it's commencing trials of its poison ivy vaccine candidate. Release

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.